# Curaleaf account plan

> Curaleaf is a vertically integrated cannabis operator in 15 U.S. states and Europe: $1,268.1 million FY2025 revenue, 5,554 employees.

## At a glance

Curaleaf Holdings is a vertically integrated cannabis company that cultivates, extracts, manufactures and sells flower, pre-rolls, vapes, edibles and other products to consumers and patients in the U.S., Canada, Europe and Australasia. In the U.S. it sells through 188 owned and managed stores in 15 states (at September 30, 2026) and over 1,300 wholesale partner accounts; internationally it mostly wholesales medical cannabis, led by Germany, the U.K. and Poland. FY2025 total revenues, net were $1,268.1 million (down 5%), Adjusted EBITDA $274.7 million (22% margin) and the net loss attributable to Curaleaf $231.1 million; it had 5,554 employees at December 31, 2025. Incorporated in British Columbia and headquartered in Stamford, Connecticut, its subordinate voting shares are listed on the TSX as CURA and quoted on the OTCQX as CURLF, with a U.S. redomicile planned.

## Business units

- **Domestic Operations** ($1,095.7 million FY2025 revenue, about 86% of group revenue): Vertically integrated U.S. cannabis business selling through its own dispensaries (online ordering, drive-thru and delivery where allowed) and wholesale to third-party dispensaries, with national brands such as Select, Grassroots, Find, Anthem, Reef and JAMS. FY2025 revenue fell 11% on retail competition and price compression, but Q3 2026 revenue grew 8% to $294.0 million on new stores in Florida and Ohio, acquired stores in Maine and more wholesale partners. President Rahul Pinto presents domestic results.
- **International Operations** ($172.5 million FY2025 revenue, about 14% of group revenue): Mostly a wholesaler of medical cannabis to pharmacies in Germany, Poland, Switzerland and the U.K., plus a U.K. clinic and pharmacy, supplied from Portugal, Canada and manufacturing in Germany, Spain and the U.K. Revenue grew 63% in FY2025 and 28% to $58.7 million in Q3 2026, helped by flower and vapes in Germany and the U.K. and the QMID inhaler. Ilya Gruzdev was appointed CFO of Curaleaf International on November 3, 2025.

## Strategic priorities

- **U.S. retail and brand share**: Strengthen the U.S. retail platform through store-level execution, product availability and customer experience, with priority states Florida, Illinois, New Jersey and Pennsylvania. The company expects to end 2026 with around 89-90 Florida stores, up from about 65, and intends to play in Georgia and Texas.
- **International expansion**: Grow patient adoption in Germany, the U.K. and Poland and open new markets: Spain sales start in November 2026, a French pharma distribution partnership targets a 2027 launch, and Turkey, where Curaleaf holds the only foreign-issued license, is expected to start in 2027.
- **International supply self-sufficiency**: About 20% of international supply comes from its own facilities; the target is 50% to 75% within 6 to 12 months through Portugal and Canada expansion, acquisitions and later U.S. exports, cutting cash conversion from about 120 days to less than 60 days.
- **Cost and operating efficiency**: A plan to cut $20 million of expenses in H2 2026 and a program to take $35 to $40 million out of SG&A over 12 months, alongside supply chain modernization and investment in data analytics, merchandising and assortment optimization.
- **Federal reform and capital markets**: Medical cannabis moved to Schedule III in April 2026, so medical activity on or after April 28, 2026 is no longer limited by Section 280E; the company is prepared to uplist the entire company to a major U.S. exchange once adult-use is rescheduled, and plans a U.S. redomicile.

## Latest results

In Q3 2026 (quarter to September 30, 2026) total revenues, net rose 11% to $352.7 million, with retail up 8% to $242.6 million and wholesale up 21% to $106.2 million; domestic grew 8% and international 28%. Gross margin fell to 48% from 51% and operating expenses rose 9% to $167.5 million, but Adjusted EBITDA increased to $77.6 million (22% margin) from $71.7 million, and the net loss from continuing operations narrowed to $37.4 million. Over nine months, revenue was $1,017.0 million (up 9%) and net income attributable to Curaleaf $49.6 million, helped by a $121.2 million release of uncertain tax positions. Management guides Q4 revenue up 1% to 2% sequentially (about $358 million at the midpoint), gross margin of 48-49%, roughly flat EBITDA, about $150 million of 2026 operating cash flow and about $80 million of capex.

## Investments and deals

- **Aurora Cannabis takeover bid**: Offer launched in August 2026 and raised on October 6, 2026 to $1.00 cash plus 0.4013 SVS per Aurora share, open until December 4, 2026. Aurora's board recommended a competing Organigram arrangement on November 3, 2026; Curaleaf says it would improve its bid only with due diligence access.
- **Four20 Pharma buyout**: The sellers of Four20 Pharma GmbH in Germany exercised their put on the remaining 45% on February 23, 2026 (expected price $80.0 million to $100.0 million, cash and stock); Curaleaf bought the 45% in April 2026.
- **Refinancing**: $500.0 million of 11.5% senior secured notes due 2029 placed on February 18, 2026 to repay the 2026 notes; the Needham revolving line was raised from $40 million to $100 million in October 2025. Notes payable were $636.9 million at September 30, 2026.
- **Store and capacity growth**: Eight new dispensaries opened in 2025 across Florida, Maine and Ohio; a facility bought in Ohio more than doubled capacity there. Capex was $63.4 million in FY2025 and is expected at about $80 million for 2026.
- **Portfolio exits**: Hemp-derived THC and Missouri were exited and reclassified as discontinued operations on December 30, 2025; cannabis beverages will be pursued only within regulated cannabis frameworks.

## Challenges and risks

- **U.S. price compression and competition**: Retail competition, new market entrants and market saturation lowered transaction volumes and prices; domestic FY2025 revenue fell 11%, and wholesale price compression hit New York, New Jersey and Illinois in Q3 2026.
- **German price collapse**: German prices fell from about $3 a gram to $0.90 a gram in one quarter as some Canadian producers dumped product, and October 2026 was described as the worst month since the market began.
- **Federal illegality and Section 280E**: Adult-use cannabis remains under Section 280E, and Schedule I status limits banking, financing and bankruptcy access; the company holds reserves for an uncertain tax position on 280E.
- **Leverage and dilution**: Notes payable of $636.9 million against cash of $104.9 million at September 30, 2026; the Aurora offer, if completed, requires cash and dilutes existing shareholders.
- **European regulatory risk**: Licensing, reimbursement, prescriber adoption, reliance on third-party distributors and protectionist policies are named risks for the international business.

## What leadership says

> "we have moved from stabilization to acceleration" — Boris Jordan, Chairman and Chief Executive Officer, Curaleaf Q2 2026 earnings call, August 5, 2026

> "So today we provide about 20% of our supply comes from our own facilities. We'd like to increase that to somewhere between 50% and 75%." — Boris Jordan, Chairman and Chief Executive Officer, Curaleaf Q2 2026 earnings call, August 5, 2026

> "It's not the EU GMP certification that's the most important thing. It's the supply chain that's the most important thing and at the right price." — Boris Jordan, Chairman and Chief Executive Officer, Curaleaf Q3 2026 earnings call, November 3, 2026

> "We intend to end the year at around 89, 90 stores in Florida" — Boris Jordan, Chairman and Chief Executive Officer, Curaleaf Q3 2026 earnings call, November 3, 2026


## Where a supplier can help

- **EU-GMP contract supply and logistics**: Tied to the international supply priority: with only about 20% of supply from its own facilities and a 50% to 75% target, EU-GMP cultivators, contract manufacturers and pharma logistics providers can help raise margins and shorten cash conversion.
- **Retail analytics and merchandising tools**: Tied to U.S. price compression and the 2026 push into data analytics, merchandising and assortment optimization: pricing, loyalty and store-execution software can support share gains in priority states.
- **Florida store build-out**: Tied to the plan to reach around 89-90 Florida stores by end of 2026: fit-out, security, fixtures and point-of-sale suppliers serve a fast-growing store base.
- **Cost-reduction programs**: Tied to the $35 to $40 million SG&A program and the company's AI committee deploying tools in pricing, merchandising, IT, legal, finance and operations: automation and outsourcing vendors can show measurable savings.
- **Market-entry services in new countries**: Tied to international expansion into Spain, France and Turkey: regulatory, pharmacy distribution and patient-education partners can speed launches.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 40-F for 2025: Annual Information Form, MD&A and Consolidated Financial Statements](https://www.sec.gov/Archives/edgar/data/1756770/000175677026000019/curlf-20251231_d2.htm)

Annual report · 2026-02-27

- Curaleaf Holdings is a vertically integrated, multi-state cannabis operator (incorporated in British Columbia, headquartered in Stamford, Connecticut; SVS listed on the TSX as CURA and quoted on the OTCQX as CURLF) serving consumers and patients across the U.S., Canada, Europe and Australasia.
- FY2025 Total revenues, net were $1,268.1 million, down 5% from $1,334.3 million; gross profit was $631.0 million (50% margin vs 48%); net loss attributable to Curaleaf was $231.1 million; Adjusted EBITDA was $274.7 million (22% margin) vs $303.3 million.
- Two reportable segments: Domestic Operations ($1,095.7 million revenue, down 11%, Adjusted EBITDA margin 23%) and International Operations ($172.5 million, up 63%, Adjusted EBITDA margin 14%).
- U.S. footprint at year-end 2025: 15 states, 159 retail locations (70 in Florida), over 1,300 wholesale partner accounts; 17 cultivation sites with approximately 1.5 million square feet of capacity. Retail was 73% and wholesale 26% of FY2025 revenue.
- Domestic revenue decline was driven by retail competition, new market entrants, market saturation, lower transaction volumes and pricing compression; international growth came from German flower sales, U.K. pharmacy demand and higher patient counts.
- Strategy pillars: domestic market leadership in limited-license states (Florida, Illinois, New Jersey, Pennsylvania), international expansion (it believes it is the largest cannabis operator in Europe; licenses awarded in Turkey and Australia in 2025), and science-led R&D.
- Portfolio actions: exit from hemp-derived THC and Missouri (reclassified as discontinued operations on December 30, 2025); eight new dispensaries opened in 2025 across Florida, Maine and Ohio; added to the S&P/TSX Composite Index on September 22, 2025.
- Balance sheet: $500.0 million of 11.5% senior secured notes due 2029 placed on February 18, 2026 to repay the 2026 notes; Needham revolving line raised to $100 million; cash of $101.6 million and working capital of $154.3 million at year-end; FY2025 capital expenditures of $63.4 million.
- Main risks: cannabis remains Schedule I under U.S. federal law (Section 280E, banking, bankruptcy access), competition from illicit and hemp-derived products, European regulatory and licensing risk, and an uncertain tax position on Section 280E. Rescheduling to Schedule III, if finalized, would remove 280E for those products.
- Leadership: Boris Jordan (CEO and Chairman, control person), Joseph Lusardi (Executive Vice Chairman), Rahul Pinto (President, appointed June 16, 2025), Ed Kremer (CFO); the company had 5,554 employees at December 31, 2025.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1756770/000162828026069653/curlf-20260930.htm)

Interim report · 2026-11-03

- Q3 2026 Total revenues, net were $352.7 million, up 11% from $317.9 million; retail $242.6 million (up 8%), wholesale $106.2 million (up 21%).
- Domestic revenue grew 8% to $294.0 million (new stores mainly in Florida and Ohio, acquired stores in Maine, more wholesale partners and better flower quality); International grew 28% to $58.7 million (flower and vapes in Germany and the U.K., more active patients, launch of the QMID inhaler).
- Gross margin fell to 48% from 51%; operating expenses rose 9% to $167.5 million (headcount, bonuses, PSUs, litigation and Aurora bid costs); Adjusted EBITDA was $77.6 million (22% margin) vs $71.7 million.
- Net loss from continuing operations narrowed to $37.4 million from $54.3 million as the tax provision fell after the Rescheduling Order; nine-month net income attributable to Curaleaf was $49.6 million, helped by a $121.2 million release of uncertain tax positions and a $60.5 million valuation allowance release.
- Footprint: 15 states, 188 owned and managed U.S. stores at September 30, 2026 (191 by November 3, 2026), over 1,300 wholesale accounts, medical cannabis patients in 15 countries.
- Takeover bid for Aurora Cannabis: amended on October 6, 2026 to $1.00 cash plus 0.4013 SVS per Aurora share, open until December 4, 2026; on November 3, 2026 Aurora's board recommended a competing Organigram arrangement.
- Balance sheet: cash $104.9 million, working capital $175.8 million, notes payable $636.9 million (mostly the $500 million 2029 notes); 1-for-3 reverse split on June 5, 2026; NCIB for up to 11.4 million SVS.
- Medical cannabis activity on or after April 28, 2026 is no longer limited by Section 280E; a U.S. redomicile is planned.

### [Curaleaf Q3 2026 earnings call transcript](https://equibles.com/stocks/curlf/calls/2026-q3)

Executive talk · Boris Jordan, Chairman and Chief Executive Officer · 2026-11-03

- Q3 2026 record revenue of $353 million (up 11%): domestic up 8%, international up 28%; adjusted gross margin 49%; adjusted EBITDA $78 million (22% margin); cash $105 million.
- Aurora bid: Organigram's rival offer was "just under 10%" better on the day; Jordan said Curaleaf "is going to improve our bid substantially" but requires due diligence access before December 4.
- Germany: prices fell from about $3 a gram to $0.90 a gram in one quarter as some Canadian producers dumped product; October was the worst month since the market began; Curaleaf has filed evidence of greenwashing with regulators.
- Domestic: retail transactions up 10%, Anthem up 185%, Find up 30% and now number one flower brand in New York; yields up 15%; plan to cut $20 million of expenses in H2 2026.
- Florida: the company expects to end 2026 with around 89-90 stores versus about 65 at the start of the year; openings will slow in 2027.
- DEA registrations: more than 80 already received for medical locations after medical rescheduling.
- Outlook: Q4 revenue up 1% to 2% sequentially (about $358 million midpoint), gross margin 48-49%, EBITDA roughly flat; operating cash flow target of about $150 million for 2026; capex about $80 million.
- New markets: Spain sales start this month, French pharma distribution partnership for a 2027 launch, Turkey rules in early 2027.

### [Curaleaf Q2 2026 earnings call transcript](https://equibles.com/stocks/curlf/calls/2026-q2)

Executive talk · Boris Jordan, Chairman and Chief Executive Officer · 2026-08-05

- Boris Jordan framed the Q2 2026 call as his two-year anniversary as CEO: the business has "moved from stabilization to acceleration" under the Built for Growth framework introduced in March.
- Q2 revenue was $340 million, 10% organic growth; domestic up 7% and international up 26%; gross margin 50%; adjusted EBITDA $70 million (21% margin); net income from continuing operations $12.5 million.
- International supply is the biggest issue: about 20% of supply comes from its own facilities, with a target of 50% to 75% within 6 to 12 months via Portugal and Canada expansion, acquisitions and later U.S. exports.
- April rescheduling moved state-regulated medical cannabis to Schedule III; 280E now applies only to adult-use; the company is prepared to uplist the entire company to a major U.S. exchange once adult-use is rescheduled.
- Jordan expects industry organic growth of 10% to 15% in 2027 as the inhalable hemp loophole closes, and possible price increases.
- A cost program is to remove $35 to $40 million from SG&A over 12 months; 2026 capex expected at about $80 million; Q3 revenue guided to about $347 million at the midpoint.
- New markets: Spain (first approvals for two cannabis medicines), France (pharma distribution partner), Turkey (launch expected 2027); in the U.S., Curaleaf intends to play in Georgia and Texas.

## Questions about Curaleaf

### What does Curaleaf do?

Curaleaf is a vertically integrated cannabis company that grows, processes and sells cannabis products through its own U.S. dispensaries and wholesale accounts, and supplies medical cannabis in Europe and Australasia.

### What is Curaleaf's revenue?

FY2025 total revenues, net were $1,268.1 million, down 5% from $1,334.3 million. Q3 2026 revenue was $352.7 million, up 11%.

### How many employees does Curaleaf have?

Curaleaf had 5,554 employees at December 31, 2025: 4,862 in the U.S., 92 in Canada, 598 in Europe and 2 in Australia.

### Who leads Curaleaf?

Boris Jordan is Chairman and CEO, Rahul Pinto is President, Ed Kremer is CFO and Joseph Lusardi is Executive Vice Chairman.

### What is Curaleaf's strategy?

It pursues U.S. market leadership in limited-license states, international expansion in medical markets such as Germany, the U.K., Poland, Spain, France and Turkey, and science-led R&D, under its Built for Growth framework.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
